Resultats de la cerca - David C. Fajgenbaum

Refinar resultats
  1. 1
    Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

    Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease per David C. Fajgenbaum

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Overview of Castleman disease

    Overview of Castleman disease per Angela Dispenzieri, David C. Fajgenbaum

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate

    Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate per Puja Mehta, David C. Fajgenbaum

    Publicat 2021
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Teaching Old Drugs New Tricks: Statins for COVID-19?

    Teaching Old Drugs New Tricks: Statins for COVID-19? per David C. Fajgenbaum, Daniel J. Rader

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Cytokine Storm

    Cytokine Storm per David C. Fajgenbaum, Carl H. June

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy

    HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy per David C. Fajgenbaum, Frits van Rhee, Christopher S. Nabel

    Publicat 2014
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy

    Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy per Sudipto Mukherjee, Rabecka Martin, Brenda Sande, Jeremy S. Paige, David C. Fajgenbaum

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Rare Disease Drug Repurposing

    Rare Disease Drug Repurposing per Sally Nijim, Ania Korsunska, Joseph Zinski, Sarah E. Bolden, Mary Zuccato, Mileva Repasky, David C. Fajgenbaum

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Castleman disease

    Castleman disease per Antonino Carbone, Margaret Borok, Blossom Damania, Annunziata Gloghini, Mark N. Polizzotto, Raj Jayanthan, David C. Fajgenbaum, Mark Bower

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    The full spectrum of Castleman disease: 273 patients studied over 20 years

    The full spectrum of Castleman disease: 273 patients studied over 20 years per Éric Oksenhendler, David Boutboul, David C. Fajgenbaum, Adrien Mirouse, Claire Fieschi, Marion Malphettes, Laëtitia Vercellino, Véronique Meignin, Laurence Gérard, Lionel Galicier

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease

    Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease per Lu Zhang, Ailin Zhao, Minghui Duan, Zhiyuan Li, Xinxin Cao, Jun Feng, Daobin Zhou, Dingrong Zhong, David C. Fajgenbaum, Li J

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Predictors of response to anti‐<scp>IL</scp>6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase<scp>II</scp>clinical trial data

    Predictors of response to anti‐<scp>IL</scp>6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase<scp>II</scp>clinica... per Deanna E. Morra, Sheila K. Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani, Mary Guilfoyle, Craig Tendler, Frits van Rhee, David C. Fajgenbaum

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease

    Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease per Sheila K. Pierson, Aaron J. Stonestrom, Dustin Shilling, Jason R. Ruth, Christopher S. Nabel, Amrit Singh, Yue Ren, Katie Stone, Hongzhe Li, Frits van Rhee, David C. Fajgenbaum

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    The involvement of PI3K–Akt signaling in the clinical and pathologic findings of iMCD-TAFRO and NOS subtypes.

    The involvement of PI3K–Akt signaling in the clinical and pathologic findings of iMCD-TAFRO and NOS subtypes. per Tomoka Haratake, Midori Filiz Nishimura, Asami Nishikori, Michael V. Gonzalez, Daisuke Ennishi, Ying‐Chieh Lai, Satoshi Ochi, Masatoshi Tsunoda, David C. Fajgenbaum, Frits van Rhee, Shuji Momose, Yasuharu Sato

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease

    Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease per Mateo Sarmiento Bustamante, Sheila K. Pierson, Yue Ren, Adam Bagg, Joshua D. Brandstadter, Gordan Srkalović, Natalie Mango, Daisy Alapat, Mary Jo Lechowicz, Hongzhe Li, Frits van Rhee, Megan S. Lim, David C. Fajgenbaum

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric <scp>Castleman</scp> disease

    Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multic... per Yoshito Nishimura, David C. Fajgenbaum, Sheila K. Pierson, Noriko Iwaki, Asami Nishikori, Mitsuhiro Kawano, Naoya Nakamura, Koji Izutsu, Kengo Takeuchi, Midori Filiz Nishimura, Yoshinobu Maeda, Fumio Otsuka, Kazuyuki Yoshizaki, Éric Oksenhendler, Frits van Rhee, Yasuharu Sato

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease

    Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease per Christopher S. Nabel, Stephen Sameroff, Dustin Shilling, Daisy Alapat, Jason R. Ruth, Mitsuhiro Kawano, Yasuharu Sato, Katie Stone, Signe Spetalen, Federico Valdivieso, Michael D. Feldman, Amy Chadburn, Alexander Fosså, Frits van Rhee, W. Ian Lipkin, David C. Fajgenbaum

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

    Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease per Yu Li, Meifeng Tu, Jorge E. Cortés, Zijun Y. Xu‐Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva S. Neelapu, Prajwal Boddu, Mary Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease

    Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease per Ruth-Anne Langan Pai, Alberto Sada Japp, Michael V. Gonzalez, Rozena Rasheed, Mariko Okumura, Daniel Arenas, Sheila K. Pierson, Victoria Powers, Awo Akosua Kesewa Layman, Charlly Kao, Hákon Hákonarson, Frits van Rhee, Michael R. Betts, Taku Kambayashi, David C. Fajgenbaum

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Exploring the Clinical Diversity of Castleman Disease and <scp>TAFRO</scp> Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns

    Exploring the Clinical Diversity of Castleman Disease and <scp>TAFRO</scp> Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns per Mizuna Otsuka, Tomohiro Koga, Remi Sumiyoshi, Shoichi Fukui, Yuko Kaneko, Takayuki Shimizu, Atsushi Katsube, Shingo Yano, Yasufumi Masaki, Makoto Ide, Hajime Yoshifuji, Masayasu Kitano, Yasuharu Sato, Naoki Sawa, Hiroaki Niiro, Naoya Nakamura, David C. Fajgenbaum, Frits van Rhee, Atsushi Kawakami

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: